Macquarie Group’s Anika Therapeutics ANIK Stock Holding History

Macquarie Group’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-580	Closed	-$13.3K	–	2290
2022 Q2	$13K	Hold	580	–	–	﹤0.01%	2400
2022 Q1	$15K	Hold	580	–	–	﹤0.01%	2444
2021 Q4	$21K	Hold	580	–	–	﹤0.01%	2380
2021 Q3	$25K	Hold	580	–	–	﹤0.01%	2398
2021 Q2	$25K	Sell	580 -98	-14%	-$4.17K	﹤0.01%	2313
2021 Q1	$28K	Sell	678 -322	-32%	-$12.2K	﹤0.01%	2202
2020 Q4	$45K	Hold	1,000	–	–	﹤0.01%	2062
2020 Q3	$35K	Hold	1,000	–	–	﹤0.01%	2024
2020 Q2	$38K	Hold	1,000	–	–	﹤0.01%	1991
2020 Q1	$29K	Hold	1,000	–	–	﹤0.01%	1888
2019 Q4	$52K	Sell	1,000 -1,700	-63%	-$98.8K	﹤0.01%	1847
2019 Q3	$148K	Sell	2,700 -3,900	-59%	-$200K	﹤0.01%	1654
2019 Q2	$268K	Buy	+6,600	New	+$241K	﹤0.01%	1516
2019 Q1	–	Sell	-600	Closed	-$20K	–	1656
2018 Q4	$20K	Sell	600 -100	-14%	-$3.61K	﹤0.01%	1787
2018 Q3	$30K	Sell	700 -300	-30%	-$11.9K	﹤0.01%	1812
2018 Q2	$32K	Buy	+1,000	New	+$41.2K	﹤0.01%	2008

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Macquarie Group's ANIK Position: Q3 2022 in Review

Macquarie Group sold out of Anika Therapeutics (ANIK) in Q3 2022, closing a stake of 580 shares — an estimated $13.3K sold.

Macquarie Group first reported a position in ANIK in Q2 2018 and held it in 16 quarters. The position peaked at $268K in Q2 2019. 121 funds tracked by Wall St. Rank hold ANIK as of Q3 2022.

Macquarie Group reported no remaining Anika Therapeutics position as of Q3 2022 after selling out during the quarter.
Macquarie Group sold 580 Anika Therapeutics shares in Q3 2022, an estimated $13.3K.
Macquarie Group first reported a position in Anika Therapeutics in Q2 2018 and held it in 16 quarters.
Macquarie Group's Anika Therapeutics position peaked at $268K in Q2 2019.
121 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2022.

Based on Macquarie Group's 13F filing for Q3 2022, filed 14 Nov 2022.